Article
Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
All News
Article
The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Article
The Spondyloarthritis Advances pod presented during the RheumNow Live 2021 conference featured three speakers, including an excellent lecture by Dr. Robert Wang, ophthalmology, on HLA B27 iritis and practical tips for rheumatologists.
Article
Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.
Article
Several weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective" about what disorders and diseases they would treat or just be a generalist.
Article
Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.
Article
Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.
Article
The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.
Article
Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.
Dr. John Cush
Tweet
Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi
Dr. John Cush
Tweet
Want to ask a question for the RheumNow Podcast? Record your question in 1 minute or less and we may feature it on an upcoming episode.
https://t.co/hOWU67uY1Y https://t.co/ooph09KuL9
Dr. John Cush
Tweet
Spondyloarthritis faculty panel with audience Q&A #RNL2021 https://t.co/iSosAtHLCZ
Dr. John Cush
Tweet
Dr. Artie Kavanaugh leading the spondyloarthritis pod focusing on enthesitis and dactylitis management. #RNL2021 https://t.co/NCUwabTXVd
Nigil Haroon MD, PhD 💎🦜🌎🩺🔬
Tweet
Join me at the @RheumNow SpA session happening now! #rheumatology #spondyloarthritis #ankylosing https://t.co/CTLq0xWQys
Dr. John Cush
Tweet
News Feature: Are You a Super Rheum?
https://t.co/LsGpFNXlkp https://t.co/Q9iojEQNqL
Dr. John Cush
Tweet
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH
Dr. John Cush
Tweet
Phase III RCT of apremilast showed no benefit in ankylosing spondylitis pts. 490 AS pts recv placebo or apremilast 20 mg or 30 mg bid 24 wks. The ASAS 20 was the same in all groups (PBO: 37%; 20 mg 35%; 30 mg 33). 2 yrs Xray changes were equal too. https://t.co/ILYtVMZp80
Dr. John Cush
Tweet
News Feature: Enthesitis Responses to Secukinumab in Spondylitis Patients
https://t.co/U7qfwwA2as https://t.co/lFa5LdfkIZ
Dr. John Cush
Tweet
The Reflecting Rheum: 2020 SpA and Still’s Disease Highlights
Sponsored by Novartis Medical Affairs
Listen to a discussion of medical experts share their views on the most impactful work done in spondyloarthritis and Still’s disease in 2020.
https://t.co/rxTAwQNalx https://t.co/HixhdoIIcB
Dr. John Cush
Tweet
We are three weeks out from RheumNow Live. Are you planning on attending?
https://t.co/vJlU0Z3Q3x
